OLYSIO® sales during the second quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the
global second quarter net sales of OLYSIO® (simeprevir) amounted to 264 MUSD, of
which 50 MUSD were sales in the USA.

The royalty for the second quarter amounted to 166 MSEK (17.9 MEUR). Medivir’s
royalties based on sales for the second quarter are calculated from the second
royalty tier. In addition Medivir has received a currency adjustment of 24 MSEK
(2.6 MEUR) related to 2014. The total royalty income reported for the second
quarter will therefore amount to 190 MSEK (20.5 MEUR).

+---------------------------+--------+-------+------+
|OLYSIO® global net sales   | Sales in MUSD  |      |
+---------------------------+--------+-------+------+
|Market                     |Q2 -2015|Q2-2014|Change|
+---------------------------+--------+-------+------+
|     US                    |   50   |  725  | -93% |
+---------------------------+--------+-------+------+
|     RoW                   |  214   |  106  | 101% |
+---------------------------+--------+-------+------+
|Total global net sales MUSD|  264   |  832  | -68% |
+---------------------------+--------+-------+------+

Medivir will publish its second quarter report on August 20, 2015 at 8.30 CET
followed by a conference call for investors, analysts and the media at 14.00
CET. More information about the conference call/webcast will be posted at
www.medivir.com.
For more information please contact:
Ola Burmark, CFO, Medivir AB, mobile: +46 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 14.00 CET on 14 July 2015.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.